Khiron Life Sciences Announces Closing of the Sale of Its European Business
Khiron Life Sciences Announces Closing of the Sale of Its European Business
About Khiron Life Sciences Corp. Toronto, Ontario--(Newsfile Corp. - November 17, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) ("Khiron" or the "Company") is pleased to announce that the Company has completed the sale of its European subsidiaries, being Khiron Europe GmbH ("Khiron Europe"), Zerenia Clinics Limited ("Zerenia UK"), PharmaDrug Production GmbH ("Pharmadrug"), Khiron Life Sciences UK Limited ("Khiron UK") and Khiron Life Sciences Spain SL ("Khiron Spain", and collectively with Khiron Europe, Zerenia UK, Pharmadrug and Khiron UK, the "Subject Subsidiaries", and each, a "Subject Subsidiary") to 2518542 Alberta Ltd. (the "Purchaser"), a company controlled by Avonlea-Drewry Holdings Inc. for an aggregate base purchase price of $3,000,000 (the "Transaction").
安大略省多倫多--（Newsfile Corp.，2023 年 11 月 17 日）-凱龍生命科學公司（多倫多證券交易所：KHRN）（OTCQX：KHRNF）（”Khiron“或者”公司“）很高興地宣佈，該公司已完成對其歐洲子公司的出售，即Khiron Europe GmbH（”凱龍歐洲“），澤雷尼亞診所有限公司（”Zerenia UK“)，PharmaDrug Production GmbH（”藥品“），凱龍生命科學英國有限公司（”Khiron UK“) 和 Khiron Life Sciences 西班牙 SL (”Khiron 西班牙“，再加上 Khiron Europe、Zerenia UK、Pharmadrug 和 Khiron UK，”標的子公司“，每個，一個”主題子公司“) 到 2518542 Alberta Ltd.（那個”購買者“），一家由Avonlea-Drewry Holdings Inc.控制的公司，總基本收購價爲300萬美元（即”交易“)。
Pursuant to the terms of an amended and restated share purchase agreement dated November 15, 2023 between the Company and Purchaser (the "Restated Purchase Agreement"), the base purchase price was partially satisfied by a pre-paid deposit of $500,000 and the prior advance of growth capital in an aggregate amount of $1,450,000 to the Company from the Purchaser. In accordance with the Restated Purchase Agreement, the balance of the purchase price was to be satisfied by way of a three-year, unsecured, non-interest bearing vendor take-back promissory note to be issued by the Purchaser (the "VTB Note"). However, as a result of further adjustments made to the base purchase price for the Subject Subsidiaries' closing working capital and indebtedness, which adjustments were made in accordance with the Restated Purchase Agreement, no further amount of the purchase price was owed and therefore no VTB Note was delivered by the Purchaser upon the completion of the Transaction.
根據公司與買方於2023年11月15日簽訂的經修訂和重述的股票購買協議的條款（“重述的購買協議“），買方預付的50萬美元存款和先前向公司預付的總額爲1450,000美元的增長資本部分滿足了基本收購價格。根據重述的購買協議，收購價的餘額將通過買方發行的爲期三年、無擔保、無利息的供應商收回本票來支付（“VTB 注意事項“)。但是，由於對標的子公司期末營運資金和負債的基本收購價格進行了進一步調整，這些調整是根據重列的購買協議進行的，因此沒有再欠收購價款，因此買方在交易完成後沒有交付任何VTB票據。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險投資交易所及其監管服務提供商（該術語在多倫多證券交易所風險交易所的政策中定義）均不對本新聞稿的充分性或準確性承擔責任。
About Khiron Life Sciences Corp.
關於凱龍生命科學公司
Khiron is a leading global medical cannabis company with core operations in Latin America. Leveraging wholly owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and focus on creating access to drive prescriptions and brand loyalty with patients worldwide. The Company is led by its co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and board of directors.
Khiron是一家全球領先的醫用大麻公司，在拉丁美洲擁有核心業務。利用全資醫療健康診所和專有的遠程醫療平台，Khiron將以患者爲導向的方法、醫生教育計劃、科學專業知識、產品創新相結合，並專注於創造渠道，以提高全球患者的處方和品牌忠誠度。公司由其聯合創始人兼首席執行官阿爾瓦羅·託雷斯以及經驗豐富、多元化的執行團隊和董事會領導。
Contact:
Alvaro Torres
Chief Executive Officer
Tel: +57 17442064
聯繫人：
阿爾瓦羅·託雷斯
首席執行官
電話：+57 17442064
Investor Contact:
E: investors@khiron.ca
投資者聯繫人：
E: investors@khiron.ca
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。
